This article is more than 5 years old. Information may no longer be current.
Top stories in hematology/oncology: Urine test may detect bladder cancer earlier, trial evaluates novel targeted therapy for kidney cancer
Among the top stories in hematology/oncology last week were two Q&As, one regarding a novel urine test that may detect bladder cancer earlier than available methods and the other focusing on a phase 2 trial that is evaluating a novel treatment approach in a specific type of kidney cancer.
Other highlights included a study that found prophylactic therapies restored ADAMTS13 activity levels prior to elective surgeries in six patients with acquired thrombotic thrombocytopenic purpura, the FDA granting fast track designation to APR-246 for the treatment of patients with myelodysplastic syndrome who have TP53 mutations and a presentation at the Community Oncology Conference that indicated treatment options in acute myeloid leukemia are changing rapidly and improving survival of young and elderly patients.
Urine test may revolutionize bladder cancer detection
A novel urine test may detect bladder cancer earlier than available methods, according to study results published in Cancer Discovery. Read more.
Trial to assess novel targeted therapy for rare form of kidney cancer
A preclinical study that yielded new insights into a rare pediatric malignancy laid the foundation for a phase 2 trial that is evaluating a novel treatment approach in a specific type of kidney cancer. Read more.
Preoperative prophylaxis may prevent relapse in acquired thrombotic thrombocytopenic purpura
Prophylactic therapies restored ADAMTS13 activity levels prior to elective surgeries in six patients with acquired thrombotic thrombocytopenic purpura, according to results of an observational study published in Journal of Thrombosis and Haemostasis. Read more.
FDA grants fast track, orphan drug designations to APR-246 for myelodysplastic syndrome
The FDA granted fast track designation to APR-246 for the treatment of patients with myelodysplastic syndrome who have TP53 mutations. Read more.
Rapidly expanding treatment options improving survival in acute myeloid leukemia
Treatment options in acute myeloid leukemia are changing rapidly and improving survival of young and elderly patients, according to a presenter at Community Oncology Conference. Read more.